RCM
CBIO

RA Capital Management’s Crescent Biopharma CBIO Stock Holding History

RA Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,535
Closed -$3.65M – 27
2018
Q3 		$3.65M Hold
2,535
– – 0.2% 25
2018
Q2 		$4.09M Hold
2,535
– – 0.27% 25
2018
Q1 		$4.12M Buy
+2,535
New +$5.27M 0.32% 27

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

RA Capital Management's CBIO Position: Q4 2018 in Review

RA Capital Management sold out of Crescent Biopharma (CBIO) in Q4 2018, closing a stake of 2,535 shares — an estimated $3.65M sold.

RA Capital Management first reported a position in CBIO in Q1 2018 and held it in 3 quarters. The position peaked at $4.12M in Q1 2018. 81 funds tracked by Wall St. Rank hold CBIO as of Q4 2018.

  • RA Capital Management reported no remaining Crescent Biopharma position as of Q4 2018 after selling out during the quarter.
  • RA Capital Management sold 2,535 Crescent Biopharma shares in Q4 2018, an estimated $3.65M.
  • RA Capital Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 3 quarters.
  • RA Capital Management's Crescent Biopharma position peaked at $4.12M in Q1 2018.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2018.

Based on RA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.